NCT07468916 2026-03-13
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Jonsson Comprehensive Cancer Center
Phase 2 Not yet recruiting
Clinical Trials
12 trialsNCT02001818 2024-08-06
PInNACLe
Australasian Leukaemia and Lymphoma Group
Phase 2 Completed
NCT00573378 2023-01-25
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT01387763 2022-04-27
DALIAH
Odense University Hospital
Phase 3 Completed
NCT01933906 2019-01-04
Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 1 Completed
NCT00037882 2018-11-01
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00415857 2018-08-21
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01949805 2016-11-28
PROUD-PV
AOP Orphan Pharmaceuticals AG
Phase 3 Completed
NCT00050531 2016-05-11
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00303290 2015-11-26
PEG Interferon Alpha 2B and Low-Dose Ara-C in Early Chronic Phase CML
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01227356 2010-10-25
A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia
Uppsala University
Phase 2 Completed
NCT00511121 2007-08-03
Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)
University of Bologna
Phase 2 Terminated